Compile Data Set for Download or QSAR
Report error Found 175 Enz. Inhib. hit(s) with all data for entry = 11682
TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM50443853(CHEMBL3091519 | US20230391761, Reference 1)
Affinity DataIC50: 0.190nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM50443853(CHEMBL3091519 | US20230391761, Reference 1)
Affinity DataIC50: 0.430nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639340(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-{[(5-chloro-2...)
Affinity DataIC50: 0.450nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639343(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 0.480nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639321(Methyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-N-{...)
Affinity DataIC50: 0.490nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.490nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.510nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639346(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.520nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639322(Methyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-[...)
Affinity DataIC50: 0.540nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.560nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639344(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.610nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639342(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-{[(5-chloro-2...)
Affinity DataIC50: 0.630nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.660nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639338(Methyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-{...)
Affinity DataIC50: 0.680nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639346(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.680nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.710nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639342(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-{[(5-chloro-2...)
Affinity DataIC50: 0.740nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639339(Methyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-{...)
Affinity DataIC50: 0.760nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.780nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.780nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639348(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 0.790nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639341(2-(1-Methyl-1H-imidazol-5-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.830nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 0.850nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639341(2-(1-Methyl-1H-imidazol-5-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.890nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639347(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 0.930nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639319(2-(Dimethylamino)ethyl 3-{[(5-chloro-2-thienyl)car...)
Affinity DataIC50: 1.10nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639345(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 1.10nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639340(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-{[(5-chloro-2...)
Affinity DataIC50: 1.70nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639343(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 1.80nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639320(1-Methylpiperidin-4-yl 3-{[(5-chloro-2-thienyl)car...)
Affinity DataIC50: 2.30nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639346(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 4nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 4.5nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 4.60nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639346(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 4.90nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 4.90nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 5.20nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 5.30nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 5.80nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 5.90nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639349(US20230391761, Example 2 | 2-(1-Methyl-1H-imidazol...)
Affinity DataIC50: 6nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639322(Methyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-[...)
Affinity DataIC50: 9.70nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639348(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 10nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639319(2-(Dimethylamino)ethyl 3-{[(5-chloro-2-thienyl)car...)
Affinity DataIC50: 15nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639344(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 16nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639347(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 18nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639321(Methyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-N-{...)
Affinity DataIC50: 26nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639343(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 33nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639345(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 35nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639339(Methyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-{...)
Affinity DataIC50: 52nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM639348(3-(1-Methyl-1H-imidazol-2-yl)propyl 3-[(5-chloroth...)
Affinity DataIC50: 62nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 175 total ) | Next | Last >>
Jump to: